世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

初代細胞市場:タイプ毎(ヒト初代細胞、動物初代細胞)、出所毎(造血、血液、皮膚、消化管、肝細胞、腎、外骨格、筋肉)、エンドユーザ毎(ライフサイエンス研究、研究機関) - 2023年までの世界市場予測

Primary Cells Market by Type (Human Primary Cells, Animal Primary Cells), Origin (Hematopoietic, Blood, Skin, Gastrointestinal, Hepatocytes, Renal, Skeleton & Muscles), End User (Life Science Research & Research Institutes) - Global Forecast to 2023

 

出版社 出版年月電子版価格 ページ数図表数
MarketsandMarkets
マーケッツアンドマーケッツ
2018年7月US$5,650
シングルユーザライセンス
115 106

サマリー

幅広い市場に関する調査レポートを出版しているマーケッツアンドマーケッツ(MarketsandMarkets)の初代細胞市場に関する調査レポートです。

“The global primary cells market is projected to grow at a CAGR of 8.5% during the forecast period.”

The primary cells market is expected to reach USD 1,107.3 million by 2023 from USD 736.4 million in 2018, at a CAGR of 8.5%. Factors driving the growth of this market include rising prevalence of cancer patients and rising adoption of primary cells over cell lines. However, the high cost of advanced primary cells and risk of contamination are the key factors that are expected to hamper the growth of the primary cells market. On the other hand, emerging economies such as China and Japan are providing lucrative opportunities for the players operating in the primary cells market.

“The liver cells segment is anticipated to register at the fastest rate in the next five years.”

On the basis of origin, the primary cells market is categorized into hematopoietic, skin, gastrointestinal, liver, lung, renal, heart, skeletal & muscle, and other primary cells. The demand for liver cells is increasing owing to their increasing application in toxicological and pharmacological studies. This segment is expected to witness the highest growth in the primary cells market.

The human primary cells segment is likely to achieve the fastest rate in the next five years.”

Based on type, the market is segmented into human and animal primary cells. The human primary cells are likely to achieve the fastest growth rate due to high use of these types of cells for studying human cancerous cell models, in toxicology studies, and in the cosmetic industry.

 “Asia is estimated to grow at the highest CAGR during the study period.”

Geographically, the primary cells market is dominated by North America, followed by Europe in 2017. However, Asia Pacific is estimated to grow at the fastest rate due to increasing research funding for cancer research, growing life science research sector in China, and increasing government support to promote life science research projects in the region.

The primary interviews conducted for this report can be categorized as follows:

- By Company Type: Tier 1-35%, Tier 2-22% and Tier 3- 43%
- By Designation: C level-15%, Director level-32%, Others-53%
- By Region: North America-34%, Europe-27%, Asia-23%, Rest of the World-16%

The major players in this market are Thermo Fisher Scientific (US), Merck KGaA (Germany), Lonza (Switzerland), Cell Biologics (US), PromoCell (Germany), ZenBio (US), STEMCELL Technologies (Canada), AllCells (US), American Type Culture Collection (US), and Axol Biosciences (UK).

Research Coverage:

The report analyses the primary cells market by origin, type, method, end user, and region. Apart from a comprehensive geographic product analysis and market sizing, the report also provides a competitive landscape that covers growth strategies adopted by industry players over the last three years. In addition, the company profiles include product portfolios, developments, and strategies adopted by prominent market players to maintain and increase their shares in the market. Market research data, current market size, and forecast of the future trends will help key market players and new entrants make the necessary decisions regarding product offerings, geographic focus, change in strategic approach, and levels of output to remain successful.

Key Benefits of Buying the Report:

This report will enable both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help firms garner greater market shares. Firms purchasing the report can use one or a combination of the below mentioned five strategies for strengthening their market shares.

The report provides insights on the following pointers:

- Market Penetration: Comprehensive information on the product portfolios of the top players in the primary cells market
- Product Development/Innovation: Detailed insights on upcoming technologies, R&D activities, and product launches in the primary cells market
- Competitive Assessment: In-depth assessment of the market strategies, geographic, and business segments and product portfolios of the leading players in the primary cells market
- Market Development: Comprehensive information about emerging markets. This report analyses the market for various primary cells types across geographies
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the primary cells market



目次

1 INTRODUCTION 12
1.1 OBJECTIVES OF THE STUDY 12
1.2 MARKET DEFINITION 12
1.3 MARKET SCOPE 13
1.3.1 YEARS CONSIDERED FOR THE STUDY 13
1.4 CURRENCY 14
1.5 LIMITATIONS 14
1.6 STAKEHOLDERS 14

2 RESEARCH METHODOLOGY 15
2.1 RESEARCH DATA 15
2.1.1 SECONDARY DATA 16
2.1.1.1 Key data from secondary sources 16
2.1.2 PRIMARY DATA 16
2.1.2.1 Key data from primary sources 17
2.2 MARKET SIZE ESTIMATION 18
2.2.1 BOTTOM-UP APPROACH 18
2.2.2 TOP-DOWN APPROACH 19
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 20
2.4 ASSUMPTIONS FOR THE STUDY 21

3 EXECUTIVE SUMMARY 22

4 PREMIUM INSIGHTS 25
4.1 PRIMARY CELLS: MARKET OVERVIEW 25
4.2 PRIMARY CELLS MARKET SHARE, BY REGION & ORIGIN, 2018 26
4.3 PRIMARY CELLS MARKET, BY TYPE, 2018-2023 (USD MILLION) 27
4.4 GEOGRAPHICAL SNAPSHOT OF THE PRIMARY CELLS MARKET 27

5 MARKET OVERVIEW 28
5.1 INTRODUCTION 28
5.2 MARKET DYNAMICS 28
5.2.1 DRIVERS 29
5.2.1.1 Increasing cancer research 29
5.2.1.2 Advantages of primary human cells over cell lines 30
5.2.1.3 Increasing demand for monoclonal antibodies 30
5.2.1.4 Rapid growth in the biotechnology and biopharmaceutical industries 30
5.2.1.5 Partnerships, collaborations, and acquisitions strengthening market growth 31
5.2.1.6 Increasing pharmaceutical outsourcing 32
5.2.2 RESTRAINTS 32
5.2.2.1 Concerns regarding primary cell culture contamination 32
5.2.3 OPPORTUNITIES 33
5.2.3.1 Advancing biomedical research using primary cells in 3D culture 33

6 PRIMARY CELLS MARKET, BY ORIGIN 34
6.1 INTRODUCTION 35
6.2 HEMATOPOIETIC CELLS 36
6.3 SKIN CELLS 38
6.4 GASTROINTESTINAL CELLS 39
6.5 LIVER CELLS 40
6.6 LUNG CELLS 41
6.7 RENAL CELLS 42
6.8 HEART 43
6.9 SKELETAL AND MUSCLE CELLS 44
6.10 OTHER PRIMARY CELLS 44

7 PRIMARY CELLS MARKET, BY TYPE 45
7.1 INTRODUCTION 46
7.2 HUMAN PRIMARY CELLS 47
7.3 ANIMAL PRIMARY CELLS 48

8 PRIMARY CELLS MARKET, BY END USER 49
8.1 INTRODUCTION 50
8.2 LIFE SCIENCE RESEARCH COMPANIES 51
8.3 RESEARCH INSTITUTES 52

9 PRIMARY CELLS MARKET, BY REGION 53
9.1 INTRODUCTION 54
9.2 NORTH AMERICA 55
9.2.1 US 59
9.2.2 CANADA 61
9.3 EUROPE 64
9.3.1 UK 66
9.3.2 ITALY 69
9.3.3 GERMANY 71
9.3.4 FRANCE 73
9.3.5 ROE 75
9.4 ASIA 77
9.4.1 CHINA 80
9.4.2 JAPAN 82
9.4.3 REST OF ASIA 84
9.5 REST OF THE WORLD 86

10 COMPETITIVE LANDSCAPE 88
10.1 OVERVIEW 88
10.2 MARKET SHARE RANKING, 2017 89
10.3 TOP RANKING COMPANIES IN THE PRIMARY CELLS MARKET 89
10.4 COMPETITIVE SCENARIO 90
10.4.1 PRODUCT LAUNCHES 90
10.4.2 EXPANSIONS 90
10.4.3 ACQUISITIONS 90

11 COMPANY PROFILES 91
11.1 THERMO FISHER SCIENTIFIC 91
11.1.1 BUSINESS OVERVIEW 91
11.1.2 PRODUCTS OFFERED 92
11.1.3 RECENT DEVELOPMENTS 92
11.1.4 MNM VIEW 92
11.2 MERCK KGAA 93
11.2.1 BUSINESS OVERVIEW 93
11.2.2 PRODUCTS OFFERED 94
11.2.3 RECENT DEVELOPMENTS 96
11.2.4 MNM VIEW 96
11.3 LONZA 97
11.3.1 BUSINESS OVERVIEW 97
11.3.2 PRODUCTS OFFERED 98
11.3.3 RECENT DEVELOPMENTS 98
11.3.4 MNM VIEW 99
11.4 CELL BIOLOGICS 100
11.4.1 BUSINESS OVERVIEW 100
11.4.2 PRODUCTS OFFERED 100
11.4.3 RECENT DEVELOPMENTS 100
11.5 PROMOCELL 101
11.5.1 BUSINESS OVERVIEW 101
11.5.2 PRODUCTS OFFERED 101
11.5.3 RECENT DEVELOPMENTS 101
11.6 ZENBIO 102
11.6.1 BUSINESS OVERVIEW 102
11.6.2 PRODUCTS OFFERED 102
11.6.3 RECENT DEVELOPMENTS 102
11.7 STEM CELL TECHNOLOGIES 103
11.7.1 BUSINESS OVERVIEW 103
11.7.2 PRODUCTS OFFERED 103
11.7.3 RECENT DEVELOPMENTS 103
11.8 ALLCELLS 104
11.8.1 BUSINESS OVERVIEW 104
11.8.2 PRODUCTS OFFERED 104
11.8.3 RECENT DEVELOPMENTS 105
11.9 AMERICAN TYPE CULTURE COLLECTION (ATCC) 106
11.9.1 BUSINESS OVERVIEW 106
11.9.2 PRODUCTS OFFERED 106
11.9.3 RECENT DEVELOPMENTS 106
11.10 AXOL BIOSCIENCES 107
11.10.1 BUSINESS OVERVIEW 107
11.10.2 PRODUCTS OFFERED 107
11.10.3 RECENT DEVELOPMENTS 107

12 APPENDIX 108
12.1 INSIGHTS FROM INDUSTRY EXPERTS 108
12.2 DISCUSSION GUIDE 109
12.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 111
12.4 AVAILABLE CUSTOMIZATIONS 113
12.5 RELATED REPORTS 113
12.6 AUTHOR DETAILS 114

 

LIST OF TABLES

TABLE 1 INCREASING FUNDING IN NATIONAL CANCER INSTITUTE RESEARCH, US 29
TABLE 2 CANCER RESEARCH OUTPUT AND GROWTH (2010-2014) 29
TABLE 3 LIST OF RECENT SIGNIFICANT ACQUISITIONS 31
TABLE 4 PRIMARY CELLS MARKET, BY ORIGIN, 2016-2023 (USD MILLION) 36
TABLE 5 HEMATOPOIETIC CELLS, BY TYPE 36
TABLE 6 CANCER RESEARCH OUTPUT, GROWTH, AND IMPACT, 2010-2014 37
TABLE 7 PRIMARY HEMATOPOIETIC CELLS MARKET, BY REGION,
2016-2023 (USD MILLION) 37
TABLE 8 PRIMARY SKIN CELLS MARKET, BY REGION, 2016-2023 (USD MILLION) 38
TABLE 9 PRIMARY GASTROINTESTINAL CELLS MARKET, BY REGION,
2016-2023 (USD MILLION) 39
TABLE 10 PRIMARY LIVER CELLS MARKET, BY REGION, 2016-2023 (USD MILLION) 40
TABLE 11 PRIMARY LUNG CELLS IN THE MARKET 41
TABLE 12 PRIMARY LUNG CELLS MARKET, BY REGION, 2016-2023 (USD MILLION) 41
TABLE 13 PRIMARY RENAL CELLS IN THE MARKET 42
TABLE 14 PRIMARY RENAL CELLS MARKET, BY REGION, 2016-2023 (USD MILLION) 42
TABLE 15 PRIMARY HEART CELLS MARKET, BY REGION, 2016-2023 (USD MILLION) 43
TABLE 16 PRIMARY SKELETAL AND MUSCLE CELLS MARKET, BY REGION,
2016-2023 (USD MILLION) 44
TABLE 17 OTHER PRIMARY CELLS MARKET, BY REGION, 2016-2023 (USD MILLION) 44
TABLE 18 PRIMARY CELLS MARKET, BY TYPE, 2016-2023 (USD MILLION) 46
TABLE 19 HUMAN PRIMARY CELLS MARKET, BY TYPE, 2016-2023 (USD MILLION) 47
TABLE 20 ANIMAL PRIMARY CELLS MARKET, BY TYPE, 2016-2023 (USD MILLION) 48
TABLE 21 PRIMARY CELLS MARKET, BY END USER, 2016-2023 (USD MILLION) 50
TABLE 22 PRIMARY CELLS MARKET FOR LIFE SCIENCE RESEARCH COMPANIES,
BY REGION, 2016-2023 (USD MILLION) 51
TABLE 23 PRIMARY CELLS MARKET FOR RESEARCH INSTITUTES, BY REGION,
2016-2023 (USD MILLION) 52
TABLE 24 PRIMARY CELLS MARKET, BY REGION, 2016-2023 (USD MILLION) 54
TABLE 25 NORTH AMERICA: PRIMARY CELLS MARKET, BY COUNTRY,
2016-2023 (USD MILLION) 57
TABLE 26 NORTH AMERICA: PRIMARY CELLS MARKET, BY ORIGIN,
2016-2023 (USD MILLION) 57
TABLE 27 NORTH AMERICA: PRIMARY CELLS MARKET, BY TYPE, 2016-2023 (USD MILLION) 58
TABLE 28 NORTH AMERICA: PRIMARY CELLS MARKET, BY END USER,
2016-2023 (USD MILLION) 58
TABLE 29 US: PRIMARY CELLS MARKET, BY ORIGIN, 2016-2023 (USD MILLION) 60
TABLE 30 US: PRIMARY CELLS MARKET, BY TYPE, 2016-2023 (USD MILLION) 60
TABLE 31 US: PRIMARY CELLS MARKET, BY END USER, 2016-2023 (USD MILLION) 61
TABLE 32 CANADA: PRIMARY CELLS MARKET, BY ORIGIN, 2016-2023 (USD MILLION) 62
TABLE 33 CANADA: PRIMARY CELLS MARKET, BY TYPE, 2016-2023 (USD MILLION) 63
TABLE 34 CANADA: PRIMARY CELLS MARKET, BY END USER, 2016-2023 (USD MILLION) 63
TABLE 35 R&D EXPENDITURE FOR SCIENCE AND TECHNOLOGY IN EUROPE,
2005 VS. 2015 (USD MILLION) 64
TABLE 36 EUROPE: PRIMARY CELLS MARKET, BY COUNTRY, 2016-2023 (USD MILLION) 65
TABLE 37 EUROPE: PRIMARY CELLS MARKET, BY ORIGIN, 2016-2023 (USD MILLION) 65
TABLE 38 EUROPE: PRIMARY CELLS MARKET, BY TYPE, 2016-2023 (USD MILLION) 66
TABLE 39 EUROPE: PRIMARY CELLS MARKET, BY END USER, 2016-2023 (USD MILLION) 66
TABLE 40 UK: PRIMARY CELLS MARKET, BY ORIGIN, 2016-2023 (USD MILLION) 68
TABLE 41 UK: PRIMARY CELLS MARKET, BY TYPE, 2016-2023 (USD MILLION) 68
TABLE 42 UK: PRIMARY CELLS MARKET, BY END USER, 2016-2023 (USD MILLION) 69
TABLE 43 ITALY: PRIMARY CELLS MARKET, BY ORIGIN, 2016-2023 (USD MILLION) 70
TABLE 44 ITALY: PRIMARY CELLS MARKET, BY TYPE, 2016-2023 (USD MILLION) 70
TABLE 45 ITALY: PRIMARY CELLS MARKET, BY END USER, 2016-2023 (USD MILLION) 71
TABLE 46 GERMANY: PRIMARY CELLS MARKET, BY ORIGIN, 2016-2023 (USD MILLION) 72
TABLE 47 GERMANY: PRIMARY CELLS MARKET, BY TYPE, 2016-2023 (USD MILLION) 72
TABLE 48 GERMANY: PRIMARY CELLS MARKET, BY END USER, 2016-2023 (USD MILLION) 73
TABLE 49 FRANCE: PRIMARY CELLS MARKET, BY ORIGIN, 2016-2023 (USD MILLION) 74
TABLE 50 FRANCE: PRIMARY CELLS MARKET, BY TYPE, 2016-2023 (USD MILLION) 74
TABLE 51 FRANCE: PRIMARY CELLS MARKET, BY END USER, 2016-2023 (USD MILLION) 75
TABLE 52 ROE: PRIMARY CELLS MARKET, BY ORIGIN, 2016-2023 (USD MILLION) 75
TABLE 53 ROE: PRIMARY CELLS MARKET, BY TYPE, 2016-2023 (USD MILLION) 76
TABLE 54 ROE: PRIMARY CELLS MARKET, BY END USER, 2016-2023 (USD MILLION) 76
TABLE 55 GROWTH IN THE NUMBER OF PUBLICATIONS IN CHINA AND JAPAN, 2010-2014 77
TABLE 56 ASIA : PRIMARY CELLS MARKET, BY COUNTRY, 2016-2023 (USD MILLION) 79
TABLE 57 ASIA: PRIMARY CELLS MARKET, BY ORIGIN, 2016-2023 (USD MILLION) 79
TABLE 58 ASIA: PRIMARY CELLS MARKET, BY TYPE, 2016-2023 (USD MILLION) 80
TABLE 59 ASIA: PRIMARY CELLS MARKET, BY END USER, 2016-2023 (USD MILLION) 80
TABLE 60 CHINA: PRIMARY CELLS MARKET, BY ORIGIN, 2016-2023 (USD MILLION) 81
TABLE 61 CHINA: PRIMARY CELLS MARKET, BY TYPE, 2016-2023 (USD MILLION) 82
TABLE 62 CHINA: PRIMARY CELLS MARKET, BY END USER, 2016-2023 (USD MILLION) 82
TABLE 63 JAPAN: PRIMARY CELLS MARKET, BY ORIGIN, 2016-2023 (USD MILLION) 83
TABLE 64 JAPAN: PRIMARY CELLS MARKET, BY TYPE, 2016-2023 (USD MILLION) 83
TABLE 65 JAPAN: PRIMARY CELLS MARKET, BY END USER, 2016-2023 (USD MILLION) 84
TABLE 66 ROA: PRIMARY CELLS MARKET, BY ORIGIN, 2016-2023 (USD MILLION) 84
TABLE 67 ROA: PRIMARY CELLS MARKET, BY TYPE, 2016-2023 (USD MILLION) 85
TABLE 68 ROA: PRIMARY CELLS MARKET, BY END USER, 2016-2023 (USD MILLION) 85
TABLE 69 ROW: PRIMARY CELLS MARKET, BY ORIGIN, 2016-2023 (USD MILLION) 86
TABLE 70 ROW: PRIMARY CELLS MARKET, BY TYPE, 2016-2023 (USD MILLION) 86
TABLE 71 ROW: PRIMARY CELLS MARKET, BY END USER, 2016-2023 (USD MILLION) 87

 

LIST OF FIGURES

FIGURE 1 PRIMARY CELLS MARKET 13
FIGURE 2 RESEARCH DESIGN 15
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE AND DESIGNATION 17
FIGURE 4 PRIMARY CELLS MARKET: BOTTOM-UP APPROACH 18
FIGURE 5 PRIMARY CELLS MARKET: TOP-DOWN APPROACH 19
FIGURE 6 DATA TRIANGULATION METHODOLOGY 20
FIGURE 7 PRIMARY CELLS MARKET, BY ORIGIN, 2018 VS. 2023 (USD BILLION) 22
FIGURE 8 PRIMARY CELLS MARKET, BY TYPE, 2018 VS. 2023 (USD BILLION) 23
FIGURE 9 PRIMARY CELLS MARKET, BY END USER, 2018 VS. 2023 (USD BILLION) 23
FIGURE 10 PRIMARY CELL MARKET, BY REGION, 2018 VS. 2023 (USD BILLION) 24
FIGURE 11 INCREASING CANCER RESEARCH IS DRIVING THE GROWTH OF THE PRIMARY CELLS MARKET 25
FIGURE 12 NORTH AMERICA IS ESTIMATED TO COMMAND THE LARGEST MARKET SHARE
IN 2018 26
FIGURE 13 HUMAN PRIMARY CELLS SEGMENT TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD 27
FIGURE 14 ASIA TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD 27
FIGURE 15 PRIMARY CELLS MARKET: DRIVERS, RESTRAINTS, & OPPORTUNITIES 28
FIGURE 16 LIVER CELLS SEGMENT WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD 35
FIGURE 17 HUMAN PRIMARY CELLS TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD 46
FIGURE 18 LIFE SCIENCE RESEARCH COMPANIES TO WITNESS THE HIGHEST GROWTH IN THE PRIMARY CELLS MARKET DURING THE FORECAST PERIOD 50
FIGURE 19 PRIMARY CELLS MARKET: GEOGRAPHIC ANALYSIS 54
FIGURE 20 NORTH AMERICA: CANCER INCIDENCE & MORTALITY, 2012-2035 55
FIGURE 21 NORTH AMERICA: PRIMARY CELLS MARKET SNAPSHOT 56
FIGURE 22 US: CANCER INCIDENCE & MORTALITY, 2012-2035 59
FIGURE 23 CANADA: CANCER INCIDENCE & MORTALITY, 2012-2035 61
FIGURE 24 EUROPE: CANCER INCIDENCE & MORTALITY, 2012-2035 64
FIGURE 25 UK: CANCER INCIDENCE & MORTALITY, 2012-2035 67
FIGURE 26 CAGR OF PUBLICATIONS IN CANCER RESEARCH, MEDICINE, AND ALL DISCIPLINES IN THE UK (2005-2014) 67
FIGURE 27 CAGR OF PUBLICATIONS IN CANCER RESEARCH, MEDICINE, AND ALL DISCIPLINES IN ITALY (2005-2014) 69
FIGURE 28 GERMANY: CANCER INCIDENCE & MORTALITY, 2012-2035 71
FIGURE 29 ASIA: CANCER INCIDENCE & MORTALITY, 2012-2035 77
FIGURE 30 ASIA: PRIMARY CELLS MARKET SNAPSHOT 78
FIGURE 31 CAGR OF PUBLICATIONS IN CANCER RESEARCH, MEDICINE, AND ALL DISCIPLINES IN CHINA (2005-2014) 81
-
FIGURE 32 PRODUCT LAUNCHES & EXPANSIONS, THE MOST ADOPTED GROWTH STRATEGY FROM 2015 TO 2018 88
FIGURE 33 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT 91
FIGURE 34 MERCK KGAA: COMPANY SNAPSHOT 93
FIGURE 35 LONZA: COMPANY SNAPSHOT 97

 

ページTOPに戻る

プレスリリース

[プレスリリース原文]

Primary Cells Market worth $ 1,107.3 million by 2023


July 31, 2018

The report "Primary Cells Market by Type (Human Primary Cells, Animal Primary Cells), Origin (Hematopoietic, Blood, Skin, Gastrointestinal, Hepatocytes, Renal, Skeleton & Muscles), End User (Life Science Research & Research Institutes) - Global Forecast to 2023", The primary cells market is expected to reach USD 1,107.3 million by 2023 from USD 736.4 million in 2018, at a CAGR of 8.5%.

Factors driving the growth of this market include increasing cancer research, high prevalence of cancer disorders, increasing research funding for the development of new cancer therapies, and increasing number of collaborations & acquisitions.

Hematopoietic cells segment is estimated to account for the largest share of the primary cells market in 2018.

Based on origin, the market is segment into hematopoietic, skin, gastrointestinal, liver, lung, renal, heart, skeletal & muscle, and other primary cells. The hematopoietic cells segment is witnessing a significant demand due to increasing cancer research globally. For instance, in 2014, cancer research represented more than 4% of overall research performed worldwide.

Human primary cells segment is anticipated to account for the largest share of the primary cells market in 2018.

The two major categories of primary cells by type included animal primary cells and human primary cells. Human primary cells are primarily used for various research applications, for instance, studying cancer stem cells and drug-drug interactions in cancerous cells and circulating tumor cells. The rising application areas of human stem cells and rising incidence of cancer are the key factors driving the growth of this market segment.

The life science research companies segment is estimated to grow at the highest CAGR during the forecast period.

The end user segment is further segmented into life science research companies and research institutes. The life science research companies segment is estimated to register the highest CAGR during the forecast period. The key factors that drive the growth of this segment is the rising application of primary cells in drug discovery and cancer research in life science research companies.

North America is expected to command the largest share of the market during the forecast period.

Based on region, the global primary cells market is segmented into North America, Europe, Asia, and Rest of the World (RoW). North America is estimated to dominate the primary cells market in 2017. This is mainly due to factors such as the increasing research on increasing prevalence of cancer related disorders, and presence of all key players in the region.

Key players in the primary cells market include Thermo Fisher Scientific (US), Merck KGaA (Germany), Lonza (Switzerland), Cell Biologics (US), PromoCell (Germany), ZenBio (US), STEMCELL Technologies (Canada), AllCells (US), American Type Culture Collection (US), and Axol Biosciences (UK).

 

あなたが最近チェックしたレポート一覧

  • 最近チェックしたレポートはありません。

お問合は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのお問合せはこちらのフォームから承ります

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

<無料>メルマガに登録する

 

 

ページTOPに戻る